More Articles

Teva CEO about opportunities in generics and biosimilars Generics/Research | Posted 15/03/2010

To retain its position in the long run, Teva Pharmaceutical Industries Ltd. aims at significant growth in the generic market in the years to come, says Teva CEO Mr Shlomo Yanai in an interview by M...

For complex biosimilars in EU: drop clinical comparability Biosimilars/Research | Posted 15/03/2010

Clinical trials required by European regulators to compare biosimilar products with corresponding biologic brands are surplus to requirements and may even be a barrier for the development of biosim...

Daiichi Sankyo unit to sell generic drugs in Japan Generics/News | Posted 15/03/2010

Daiichi Sankyo Co. Ltd. said on 26 February 2010 it will set up a new subsidiary in April 2010 to produce and sell generic drugs in Japan, in – according to Mr Kazuhiro Shimamura in the Wall Street...

After generics slow down in 2013: into biosimilars Pharma News | Posted 12/03/2010

Large pharmaceutical companies are consolidating their generics operations in established markets and/or expanding into emerging ones through local acquisitions or partnerships, writes Ms Doris de...

Global generics: time for consolidation and expansion Pharma News | Posted 12/03/2010

The global generic drug industry has witnessed an almost decade-long sales euphoria. Volumes and sales growth of prescription generic drugs continued to increase in 2009. At the same time, large co...

IMS Health, BCC: Generics sales continue to climb Pharma News | Posted 12/03/2010

Over the 12 months that ended September 2009, global sales of generics grew by 7.7%, up from 3.6 % the year before, IMS Health reported. This compares with the 5.7% growth seen within the overall g...

New method for producing human-like glycosylated MAbs Biosimilars/Research | Posted 11/03/2010

As reported online on 28 February 2010 in Nature Chemical Biology, Professor Lai-Xi Wang, Professor Markus Aebi and colleagues describe a new bacterial method for producing homogeneous eukaryotic N...

GTC achieves high-level production of TG20, a biobetter anti-CD20 MAb with enhanced antibody-dependent cell-mediated cytotoxicity Biosimilars/News | Posted 11/03/2010

GTC Biotherapeutics announced on 1 March 2010 that it has achieved high-level production of TG20; an anti-CD20 monoclonal antibody (MAb). The TG20 MAb, which is produced in the milk of transgenic g...